Dual-Target CAR T-Cell therapy shows promise in early lymphoma trial
NCT ID NCT05149391
First seen Feb 01, 2026 · Last updated Jun 15, 2026 · Updated 17 times
Summary
This early-phase study tested a new treatment called C-CAR039 in 3 people with B-cell Non-Hodgkin's lymphoma that had come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to recognize and attack two markers (CD19 and CD20) on cancer cells. The main goal was to check safety and side effects, while also looking at how well the cells work in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL NON-HODGKIN'S LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University Cancer Hospital
Beijing, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.